<DOC>
	<DOC>NCT00195546</DOC>
	<brief_summary>Primary: To assess the efficacy and safety of DVS-233 SR compared with placebo for treatment of vasomotor symptoms (VMS) associated with menopause and to compare the bleeding incidence of DVS-233 SR and tibolone. Secondary: To assess the effects of DVS-233 SR and tibolone on changes from baseline in weight, breast pain, and health outcomes indicators.</brief_summary>
	<brief_title>Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause</brief_title>
	<detailed_description />
	<criteria>Postmenopausal women of age 40 to 65 seeking treatment for hot flashes with last natural menstrual period (LNMP) completed at least 12 months prior to screening. Minimum of 7 moderate to severe hot flashes per day or 50 per week recorded for 7 consecutive days Body Mass Index less than or equal to 34 kg/m2 using the nomograph for BMI. History, presence, or suspicion of estrogendependent neoplasia; Malignancy, or treatment for malignancy, within the previous 2 years. Active or recent arterial thromboembolic disease; History of venous thromboembolism History of cerebrovascular accident, stroke, or transient ischemic attack Presence of major depressive disorder, bipolar disorder, psychotic disorder, or generalized anxiety disorder requiring therapy Persistent elevated blood pressure</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Menopause</keyword>
</DOC>